New Frontier Data 8.23.23New Frontier Data 8.23.23New Frontier Data 8.23.23New Frontier Data 8.23.23
  • Solutions
    • Market Segments
      • Retailers & Dispensaries Business Data Solutions: Because you Wouldn't Leave Home Without a Map. Consumer Research, Customer Acquisition, and Competitive Conquesting
      • InvestorsBusiness Intelligence Data: It's what's De-Risking Cannabis. Market Intelligence, Opportunity Modeling, Due-Diligence Validation, and Risk Mitigation
      • BrandsBecause "cool" is not a brand strategy. Find the white space, Determine the market, and Model the revenue
      • Agencies & Consultants Unleash the Power of Informed Campaigns! +160M Probable cannabis consumers, +60M Cannabis Retail Visitors, Custom Audience Builder, and Cannabis Specific Marketing Reporting
      • Academia regulatory understanding, retail business intelligence and Medical Patient Research
    • Problems Solved
      • Customer AcquisitionTarget, engage, and retain customers.
      • Market Intelligence & ForecastingMaximize your profits, minimize risks.
      • Custom Research & ReportsKnow your market, grow your business.
      • Brand Visibility & ExposureBoost your business with our sponsorships.
      • Analytics for the Medical Cannabis SectorData for healthcare, policies, and patient care.
  • Products
    • Equio Make Informed Decisions with actionable Insights
    • NXTeck Transform your approach to customer acquisition
    • Analyst Reports
    • CMedAccess extensive medical patient data
  • Resources
    • Blog
    • Case Studies
    • Events & Webinars
    • Podcast
    • Newsletter - Sign-Up Cannabit
  • Company
    • About Us
    • Board & Advisors
    • Our Partners
    • In The News
    • Press Releases & Media Kit
  • Equio Login
✕

Brazil Patient Participation Levels

  • Home
  • Cannabis Insights
  • Brazil Patient Participation Levels
img 147
Can Constellation Brands’ Entry into the Market Lead to Banking Reform?
December 2, 2017
New Frontier Data thumbnail
2 Million Patients Impacted by Failure to Renew Rohrabacher-Blumenauer Amendment?
December 7, 2017
December 3, 2017
Categories
  • Cannabis Insights
  • Cannabit
Tags
img 176
  • An estimated 22.2 million Brazilians suffer from chronic pain in the lower back and neck.
  • Were Brazil to legalize medical cannabis, within the first 36 months of sales the number of qualified patients could reach 959,000 under a restrictive list of qualifying conditions (i.e., not including chronic pain), or roughly 3.4 million under an expansive list of conditions (covering chronic pain).
  • An expansive program featuring chronic pain as a qualifying condition and patient counts of 3.4 million patients would translate to annual revenues of roughly BRL 4.4 billion (USD 1.4 billion).
Share
FacebookTwitterLinkedInPinterest
0

Related posts

New York Cannabis
August 19, 2025

New York Cannabis Market: Why Now is the Time to Build Your Foothold


Read more
Strategy starts with awareness for cannabis business in 2025
August 6, 2025

What Cannabis Operators Need to Know Right Now: August 2025 Industry Update


Read more
4 1 2025 Cannabit Alcohol use by cannabis consumers
April 1, 2025

Cannabis Infused Beverages: The New Frontier of Intoxicating Libations?


Read more

Comments are closed.

Brazil Patient Participation Levels

©2014-2025 New Frontier Data

HEADQUARTERS

5614 Connecticut Ave NW #331
Washington, DC 20015
info@nullnewfrontierdata.com
844-420-D8TA (3882)

MEDIA INQUIRIES

media@nullnewfrontierdata.com

FOLLOW US

social icon social icon social icon social icon social icon

COMPANY

FAQs
CONTACT US
CAREERS
PRESS RELEASES & MEDIA KIT
PRIVACY POLICY
TERMS OF USE